Testing an experimental TB vaccine during treatment
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether an experimental vaccine (ID93 + GLA-SE) can improve outcomes in people being treated for drug-sensitive tuberculosis. It is for those newly diagnosed or who have been on standard TB treatment for a few months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed TB that responds to the antibiotic rifampicin.
- You have been on standard TB treatment for less than 1 week, or about 3 to 4 months.
- If you have HIV, you must be on HIV treatment for at least 90 days and have a good immune system (CD4 count above 250).
- You have not had TB before.
- You are not pregnant or breastfeeding, and you agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new tuberculosis (TB) vaccine (ID93+GLA-SE) in healthy adults aged 55 to 74. It aims to see if the vaccine is safe and can help protect against TB, especially in people who may have latent (inactive) TB infection.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
This trial studies whether atorvastatin (a cholesterol medicine) can reduce ongoing inflammation after you finish standard tuberculosis (TB) treatment. If it works, it may improve how your body recovers after TB, especially by lowering inflammation-related signals.
This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This trial tests two drugs, metformin and N-acetylcysteine, to see if they can help your lungs work better after you finish tuberculosis treatment. You may join if you have active TB with lung damage and are starting standard TB therapy.
Hear when a new Tuberculosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.